JOURNAL LARCENCIELAMQUIBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL LARC-EN-CIEL-AMQUI
Company Title:
Company Description:
Keywords to Search:
Company Address:	54 Rue Du Pont #3,AMQUI,QC,Canada
ZIP Code: Postal Code:	G5J2P5
Telephone Number:	4186296919
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	271101
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	5 to 9
Sales Amount:	$1 to 2.5 million
Credit History: Credit Report:	Institution
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
LAVANT-POSTE
JOURNAL LAVANT-POSTE
JOURNAL LARC-EN-CIEL-AMQUI

Next company profile:
JONCAS A REFRIGERATION
JEAN-HUGHES GUENETTE INSURANCE
JARDINS DEMILLIE

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
New England Journal of Medicine
The New England Journal of Medicine publishes high-quality medical research, reviews, and opinions to advance medical science and improve patient care
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa
Recently Published | The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic . . .
Mepolizumab is a humanized monoclonal antibody that targets interleukin-5, a cytokine that plays a central role in eosinophilic inflammation, which is present in 20 to 40% of patients with chronic
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Tirzepatide and semaglutide are highly effective medications for obesity management The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 . . .
Limited evidence exists to support the simultaneous initiation of sodium–glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with